Published in J Thromb Haemost on December 01, 2003
Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest (1999) 5.65
Structural origins of fibrin clot rheology. Biophys J (1999) 3.68
A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest (1983) 3.05
A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest (1985) 2.72
Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol (2006) 2.61
Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol (2000) 2.58
Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J (1992) 2.27
Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest (1988) 2.23
Examination of the platelet membrane glycoprotein IIb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy. J Biol Chem (1992) 2.18
Hemostasis in the mouse (Mus musculus): a review. Thromb Haemost (1999) 2.13
Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood (1985) 1.95
Twisting of fibrin fibers limits their radial growth. Proc Natl Acad Sci U S A (1987) 1.93
Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia. Blood (1980) 1.80
Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood (2000) 1.77
Long range propagation of conformational changes in integrin alpha IIb beta 3. J Biol Chem (1993) 1.73
Carboxyl-terminal portions of the alpha chains of fibrinogen and fibrin. Localization by electron microscopy and the effects of isolated alpha C fragments on polymerization. J Biol Chem (1993) 1.72
A model for fibrinogen: domains and sequence. Science (1985) 1.53
A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res (2002) 1.53
Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood (1996) 1.52
Role of the alpha C domains of fibrin in clot formation. Biochemistry (1994) 1.51
Variable protection of beta 3-integrin--deficient mice from thrombosis initiated by different mechanisms. Blood (2001) 1.47
In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation (1997) 1.46
Fibrin assembly. Lateral aggregation and the role of the two pairs of fibrinopeptides. Biophys J (1986) 1.44
Effects of ligand-mimetic peptides Arg-Gly-Asp-X (X = Phe, Trp, Ser) on alphaIIbbeta3 integrin conformation and oligomerization. Biochemistry (1999) 1.43
Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest (1996) 1.39
A model from electron microscopy for the molecular structure of fibrinogen and fibrin. Nature (1981) 1.29
Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein IIb/IIIa receptor. Blood (1992) 1.28
Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation (2001) 1.27
Frequencies and patterns of bone marrow involvement in non-Hodgkin lymphomas: observations on the value of bilateral biopsies. Am J Hematol (1977) 1.27
Conformational transitions in the cell binding domain of fibronectin. Biochemistry (1995) 1.27
Measuring faculty effort and contributions in medical education. Acad Med (2000) 1.26
Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation (1988) 1.25
Asialo von Willebrand factor interactions with platelets. Interdependence of glycoproteins Ib and IIb/IIIa for binding and aggregation. J Clin Invest (1985) 1.22
Fibrinogen competes with von Willebrand factor for binding to the glycoprotein IIb/IIIa complex when platelets are stimulated with thrombin. Blood (1984) 1.21
Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin. J Clin Invest (1977) 1.21
The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol (1986) 1.20
Flow rate and fibrin fiber alignment. J Thromb Haemost (2010) 1.19
Recommendations for nomenclature on fibrinogen and fibrin. J Thromb Haemost (2008) 1.19
The conversion of fibrinogen to fibrin: recombinant fibrinogen typifies plasma fibrinogen. Blood (1997) 1.15
Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest (1988) 1.14
Von Willebrand's disease: combined qualitative and quantitative abnormalities. N Engl J Med (1977) 1.14
Cl- regulates the structure of the fibrin clot. Biophys J (1998) 1.13
Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood (1985) 1.13
Translational careers. Science (2009) 1.13
The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci U S A (1991) 1.12
Deglycosylation of fibrinogen accelerates polymerization and increases lateral aggregation of fibrin fibers. J Biol Chem (1988) 1.12
Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation (1999) 1.12
Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest (1990) 1.12
Evidence that platelet glycoprotein IIIa has a large disulfide-bonded loop that is susceptible to proteolytic cleavage. J Biol Chem (1989) 1.11
Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood (1986) 1.11
Studies on the Factor VIII/von Willebrand factor antigen on human platelets. Thromb Res (1975) 1.08
The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood (2000) 1.08
Poisson statistical analysis of repetitive subcloning by the limiting dilution technique as a way of assessing hybridoma monoclonality. Methods Enzymol (1986) 1.08
Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost (2011) 1.07
Influence of gamma' fibrinogen splice variant on fibrin physical properties and fibrinolysis rate. Arterioscler Thromb Vasc Biol (2003) 1.07
The shape of high molecular weight kininogen. Organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy. J Biol Chem (1994) 1.06
Fibrinogen coating density affects the conformation of immobilized fibrinogen: implications for platelet adhesion and spreading. Thromb Haemost (1998) 1.06
Reversible decrease in platelet retention by glass bead columns (adhesiveness) induced by disturbing the blood. Proc Soc Exp Biol Med (1971) 1.06
Preparation of monoclonal antibodies to murine platelet glycoprotein IIb/IIIa (alphaIIbbeta3) and other proteins from hamster-mouse interspecies hybridomas. Biochem Biophys Res Commun (1999) 1.05
Three-dimensional reconstruction of fibrin clot networks from stereoscopic intermediate voltage electron microscope images and analysis of branching. Biophys J (1995) 1.04
Hematologically important mutations: Glanzmann thrombasthenia. Blood Cells Mol Dis (1997) 1.04
Studies of the human factor VIII/von Willebrand factor protein. III. Qualitative defects in von Willebrand's disease. J Clin Invest (1975) 1.03
The ultrastructure of fibrinogen Caracas II molecules, fibers, and clots. J Biol Chem (1996) 1.02
Activation affects access to the platelet receptor for adhesive glycoproteins. J Cell Biol (1986) 1.02
Evidence that glycocalicin circulates in normal plasma. J Clin Invest (1984) 1.02
Carbohydrate deficiency of the factor VIII/von Willebrand factor Protein in von Willebrand's disease variants. Science (1976) 1.01
The effects of ristocetin and von Willebrand factor on platelet electrophoretic mobility. J Clin Invest (1978) 1.01
The thrombin receptor extracellular domain contains sites crucial for peptide ligand-induced activation. J Clin Invest (1993) 1.00
The structure of fibrinogen and fibrin: II. Architecture of the fibrin clot. Ann N Y Acad Sci (1983) 1.00
Immunological studies of factor VIII in haemophilia and von Willebrand's disease. Nat New Biol (1973) 1.00
Fibrinogen sialic acid residues are low affinity calcium-binding sites that influence fibrin assembly. J Biol Chem (1989) 1.00
Statistical analysis of repetitive subcloning by the limiting dilution technique with a view toward ensuring hybridoma monoclonality. Hybridoma (1983) 1.00
Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure. Am J Med (1979) 0.99
The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol (1995) 0.99
Binding of a fibrinogen mimetic stabilizes integrin alphaIIbbeta3's open conformation. Protein Sci (2001) 0.99
Structural studies of fibrinolysis by electron microscopy. Blood (1998) 0.97
Fibrinogen Dusart: electron microscopy of molecules, fibers and clots, and viscoelastic properties of clots. Biophys J (1996) 0.97
Crystals of modified fibrinogen: size, shape and packing of molecules. J Mol Biol (1978) 0.95
Plasma cofactors of platelet function: correlation with diabetic retinopathy and hemoglobins Ala-c. Ann Intern Med (1978) 0.95
Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol (2009) 0.93
Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro). Angiogenesis (1999) 0.93
Prenatal diagnosis of Glanzmann's thrombasthenia. Lancet (1986) 0.93
A deletion in the gene for glycoprotein IIb associated with Glanzmann's thrombasthenia. J Clin Invest (1991) 0.93
Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations of Israel: comparison of techniques for carrier detection. Br J Haematol (1986) 0.92
Effects of fibrin micromorphology on neurite growth from dorsal root ganglia cultured in three-dimensional fibrin gels. J Biomed Mater Res (1998) 0.92
Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation (1989) 0.92